Today we have 2 compounds:
Tivatinib (see the structure) against lung cancer:
Tivantinib, an oral medicine, aims to block an enzyme known as c-Met, which plays a role in the growth and spread of cancer.
Shares of cancer drug developer ArQule (ARQL) are dropping after the company disclosed problems with a clinical trial being conducted in Asia. ArQule’s development partner Kyowa Hakko Kirin of Japan suspended patient enrollment in a late-stage human study of the lung cancer drug tivantinib due to safety concerns.
Pomaglumetad methionil, or mGlu2/3 - the second failed drug, is for treatment of schizophrenia:
Eli Lilly and Co said it would stop developing an experimental schizophrenia drug after a recent analysis showed that a late-stage trial on the drug was likely to fail.
An independent futility analysis concluded that the second late-stage study on the drug was unlikely to meet the main goal of the trial, the company said .
Well, and what compound will fail next?
No comments:
Post a Comment